Sienna Gestion Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Sienna Gestion purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,141 shares of the company’s stock, valued at approximately $1,454,000.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 0.9% in the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after buying an additional 86,040 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $3,666,459,000. State Street Corp lifted its holdings in shares of IDEXX Laboratories by 4.0% in the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after buying an additional 138,956 shares during the period. Geode Capital Management LLC lifted its holdings in shares of IDEXX Laboratories by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the subject of several research analyst reports. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Stifel Nicolaus cut their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 1.6%

NASDAQ:IDXX opened at $570.00 on Tuesday. The firm has a market capitalization of $44.96 billion, a price-to-earnings ratio of 41.97, a PEG ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The business’s fifty day moving average price is $563.07 and its 200 day moving average price is $625.43.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.